Result card

  • TEC5: In what context and level of care are IVIG used?
No adaptation help available for this domain

In what context and level of care are IVIG used?

Authors: Jesús González-Enríquez, Nadine Berndt, Houria Mouas

Internal reviewers: Romana Tandara Haček, Mirjana Huic, Anna-Theresa Renner

Refer to domain search and domain methodology section.

IVIG is usually administered in hospitals, in an infusion center or health care facility, including hospital–based outpatient clinics (immunology, hematology, oncology) and ambulatory infusion centers {Duff 2006}{1}. Patients may benefit from receiving infusion treatment in outpatient settings if these settings maintain a consisting nursing staff and a physician is available during the infusion to monitor patient vital signs, in case of emergencies. For some patients, IVIG may be also infused in the home setting, usually by an experienced infusion nurse. In some situations, this practice has been found to be more cost effective and could result in improved quality of life measures. To determine whether the patient is a homecare candidate, the physician must be comfortable with the patient´s reaction to the IVIG infusion. The first few infusions should be administered with medical supervision, in a controlled setting, regardless of the longer-term plan, after which the physician assesses the overall risk. Patients also need to feel confident about starting their treatment options and should be educated about which location, if alternatives are available, would best serve to their interests (See also TEC7, B007- TEC14, B014).

In the European context this products are usually administered in public or private hospitals or hospital-based outpatient clinics, for a limited number of approved indications, under clinical protocols to ensure the appropriate management and use of IVIG.

González-Enríquez J et al. Result Card TEC5 In: González-Enríquez J et al. Description and technical characteristics of technology In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 30 October 2020]. Available from: